Blue Bell Private Wealth Management’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Blue Bell Private Wealth Management’s Portfolio IDNA Stock Details IDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.6K	Hold	55	–	–	﹤0.01%	666
2025 Q4	$1.44K	Hold	55	–	–	﹤0.01%	662
2025 Q3	$1.3K	Sell	55 -55	-50%	-$1.22K	﹤0.01%	666
2025 Q2	$2.26K	Hold	110	–	–	﹤0.01%	626
2025 Q1	$2.25K	Hold	110	–	–	﹤0.01%	619
2024 Q4	$2.49K	Hold	110	–	–	﹤0.01%	581
2024 Q3	$2.71K	Hold	110	–	–	﹤0.01%	598
2024 Q2	$2.54K	Hold	110	–	–	﹤0.01%	614
2024 Q1	$2.65K	Hold	110	–	–	﹤0.01%	619
2023 Q4	$2.53K	Hold	110	–	–	﹤0.01%	610
2023 Q3	$2.24K	Hold	110	–	–	﹤0.01%	563
2023 Q2	$2.57K	Hold	110	–	–	﹤0.01%	565
2023 Q1	$2.56K	Buy	+110	New	+$2.75K	﹤0.01%	533
2022 Q1	–	Sell	-20	Closed	-$1K	–	889
2021 Q4	$1K	Buy	+20	New	+$947	﹤0.01%	783

Other funds holding IDNA

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

PGA

Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

CCA

Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return

Blue Bell Private Wealth Management's IDNA Position: Q1 2026 in Review

Blue Bell Private Wealth Management held its iShares Genomics Immunology and Healthcare ETF (IDNA) position steady in Q1 2026 at 55 shares worth $1.6K. The position accounts for ﹤0.01% of the portfolio, ranked #666.

Blue Bell Private Wealth Management first reported a position in IDNA in Q4 2021 and has held it in 14 quarters since. The position peaked at $2.71K in Q3 2024. 60 funds tracked by Wall St. Rank hold IDNA as of Q1 2026.

Blue Bell Private Wealth Management held 55 shares of iShares Genomics Immunology and Healthcare ETF worth $1.6K as of Q1 2026.
Blue Bell Private Wealth Management left its iShares Genomics Immunology and Healthcare ETF share count unchanged in Q1 2026.
iShares Genomics Immunology and Healthcare ETF made up ﹤0.01% of Blue Bell Private Wealth Management's portfolio in Q1 2026, its #666 holding.
Blue Bell Private Wealth Management first reported a position in iShares Genomics Immunology and Healthcare ETF in Q4 2021 and has held it in 14 quarters since.
Blue Bell Private Wealth Management's iShares Genomics Immunology and Healthcare ETF position peaked at $2.71K in Q3 2024.
60 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q1 2026.

Based on Blue Bell Private Wealth Management's 13F filing for Q1 2026, filed 11 May 2026.